ストックスクリーナーアプリを入手
21.30
1.38%
0.29
前日終値:
$21.01
開ける：
$21.08
24時間の取引高:
1.10M
Relative Volume:
0.44
時価総額：
$1.85B
収益：
$139.71M
当期純損益:
$-209.36M
株価収益率:
-7.1959
EPS:
-2.96
ネットキャッシュフロー:
$-160.60M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+13.36%
6か月 パフォーマンス:
+136.67%
1年 パフォーマンス:
+51.28%
1日の値動き範囲:
$20.81
$21.34
1週間の範囲:
$20.42
$21.41
52週間の値動き範囲:
$8.58
$22.73
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
名前
Syndax Pharmaceuticals Inc
セクター
電話
781-419-1400
住所
730 THIRD AVENUE, NEW YORK, MA
SNDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
21.30 | 1.83B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-16 | 再開されました | H.C. Wainwright | Buy |
| 2025-09-10 | 再開されました | Stifel | Buy |
| 2025-09-04 | 再開されました | Guggenheim | Buy |
| 2025-08-05 | 繰り返されました | BTIG Research | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-06-28 | 開始されました | Jefferies | Buy |
| 2024-01-31 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 開始されました | Mizuho | Buy |
| 2023-10-25 | 開始されました | BofA Securities | Buy |
| 2023-10-11 | 開始されました | Goldman | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-11 | 開始されました | Guggenheim | Buy |
| 2023-04-17 | 再開されました | BTIG Research | Buy |
| 2023-01-31 | 開始されました | Stifel | Buy |
| 2023-01-03 | 開始されました | JP Morgan | Overweight |
| 2022-07-28 | 再開されました | B. Riley Securities | Buy |
| 2022-04-11 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-15 | 開始されました | Goldman | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-25 | 開始されました | Citigroup | Buy |
| 2021-02-18 | 開始されました | B. Riley Securities | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-05-22 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-05-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-01-04 | 開始されました | Robert W. Baird | Outperform |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 開始されました | FBR & Co. | Outperform |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2016-10-07 | 開始されました | Guggenheim | Buy |
| 2016-03-28 | 開始されました | Citigroup | Buy |
| 2016-03-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-03-28 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Syndax Pharmaceuticals Inc (SNDX) 最新ニュース
Syndax Pharmaceuticals (NASDAQ:SNDX) Upgraded at Wall Street Zen - MarketBeat
How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily
Commit To Buy Syndax Pharmaceuticals At $13, Earn 21.5% Using Options - Nasdaq
Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Debt Sensibly? - 富途牛牛
Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year HighTime to Buy? - MarketBeat
(SNDX) Risk Channels and Responsive Allocation - Stock Traders Daily
SNDX (Syndax Pharmaceuticals) EV-to-OCF : -4.35 (As of Dec. 21, 2025) - GuruFocus
Why Syndax Pharmaceuticals Inc. stock could outperform in 2025Earnings Trend Report & Daily Price Action Insights - Bölüm Sonu Canavarı
Syndax Pharmaceuticals (STU:1T3) EV-to-OCF : -4.13 (As of Dec. 21, 2025) - GuruFocus
Syndax Pharmaceuticals modernizes bylaws for electronic share issuance - MSN
How Syndax Pharmaceuticals Inc. stock reacts to inflationary pressures2025 Volatility Report & AI Enhanced Trading Alerts - Bölüm Sonu Canavarı
Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance - TipRanks
Published on: 2025-12-19 14:41:17 - DonanımHaber
Assenagon Asset Management S.A. Sells 255,848 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Will Syndax Pharmaceuticals Inc. stock outperform Nasdaq indexEarnings Trend Report & Real-Time Market Trend Scan - DonanımHaber
Will Syndax Pharmaceuticals Inc. stock beat EPS estimates2025 Market Overview & Community Trade Idea Sharing - ulpravda.ru
Syndax Pharmaceuticals (STU:1T3) EV-to-OCF : -3.99 (As of Dec. 19, 2025) - GuruFocus
How currency fluctuations impact Syndax Pharmaceuticals Inc. stock2025 Market Sentiment & Safe Capital Allocation Plans - ulpravda.ru
Syndax Pharma: Continuing Execution In AML (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 52-Week HighWhat's Next? - MarketBeat
Can Revuforj’s Awards Momentum Redefine Syndax Pharmaceuticals’ (SNDX) Precision Oncology Investment Narrative? - Sahm
Syndax Pharmaceuticals stock hits 52-week high at $21.27 By Investing.com - Investing.com Canada
Hudson Bay Capital Management LP Has $4.15 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Earnings Notes - Trefis
Syndax Pharmaceuticals (FRA:1T3) OCF Margin % : -153.77% (As of Sep. 2025) - GuruFocus
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Syndax Pharmaceuticals' Revuforj® Recognized as Best New Drug at 2025 Scrip Awards - Quiver Quantitative
Syndax (Nasdaq: SNDX) wins Scrip 2025 Best New Drug for FDA-approved Revuforj - Stock Titan
(SNDX) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Is Syndax Pharmaceuticals Inc 1T3 a good long term investmentCandlestick Pattern Analysis & Rapid Portfolio Expansion - earlytimes.in
Jump Financial LLC Makes New $3.57 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 52-Week HighHere's Why - MarketBeat
Syndax Pharmaceuticals (SNDX) Valuation After Strong New Revuforj Data at Major Hematology Meeting - Sahm
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Stempoint Capital LP - MarketBeat
Hsbc Holdings PLC Boosts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at BTIG Research - MarketBeat
SNDX: BTIG Reiterates "Buy" Rating with Price Target of $56 | SN - GuruFocus
TD Cowen reiterates Buy rating on Syndax Pharmaceuticals stock By Investing.com - Investing.com Canada
Syndax Pharmaceuticals (SNDX): Valuation Check After Positive Revuforj Data at the 67th ASH Meeting - Yahoo Finance
Is Syndax Pharmaceuticals Fairly Priced After Recent Oncology Pipeline Momentum? - Yahoo Finance
Transcript : Syndax Pharmaceuticals, Inc. Presents at The 67th American Society of Hematology Annual Meeting, Dec-08-2025 07 - marketscreener.com
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum - The Manila Times
Syndax Pharmaceuticals Highlights Promising Efficacy and Safety Data for Revuforj® at the 67th ASH Annual Meeting - Quiver Quantitative
Syndax Highlights Leadership in Menin Inhibition at ASH - GlobeNewswire
Syndax (Nasdaq: SNDX) posts 92% CRc in Phase 1 revumenib AML combo data at ASH 2025 - Stock Titan
Schroder Investment Management Group Buys 64,598 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Tema Etfs LLC - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Syndax Pharmaceuticals stock hits 52-week high at 20.25 USD By Investing.com - Investing.com Australia
Syndax Pharmaceuticals Inc (SNDX) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):